Efficacy and tolerability of contemporary antidepressants: results of network meta-analyses and Russian experience

Medvedev V.E.

doi:https://doi.org/10.17116/jnevro2018118111109

Close metadata

Recommended articles:

Pathogenetic interrelations of hypogonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

Effect of polymorphic variants of the HTR2A gene on the effectiveness and safety of sertraline in patients with mixed anxiety-depressive disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84

Effectiveness and tolerability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):90-98

Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138

Prevention of recurrent laryngeal nerve injury in thyroid surgery: a systematic review and meta-analysis. Pirogov Russian Journal of Surgery. 2025;(3):140-148

Prevalence of postpartum depression in the Russian Federation: a systematic review and meta-analysis. Medical Technologies. Assessment and Choice. 2025;(2):74-87

Neuropathic pain in chronic inflammatory demyelinating polyneuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53

Associations between salivary melatonin and periodontal disease: a systematic review and meta-analysis. Stomatology. 2025;(3):87-96

Systemic review and meta-analysis of the three-component drug regimen (alpha-glutamyl-tryptophan, bendazole, ascorbic acid) prophylactic efficacy. Russian Journal of Preventive Medicine. 2025;(8):48-55

Psychodermatological aspects of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):403-411

Abstract:

The objective of this review is to compare results of network metaanalyses of the efficacy and tolerability of different antidepressants for treatment of unipolar depression in adults. An analysis of different criteria of antidepressant efficacy and tolerability showed the benefits of agomelatine. Results of using this drug in national clinical practice and multicenter studies of depression of different nosology with heterogeneous psychopathological symptoms support this notion.

Keywords:

antidepressants

metaanalysis

agomelatin

Authors:

Medvedev V.E.

Peoples Friendship University of Russian

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Close metadata

References:

Medvedev VE. Metaanaliz pri otsenke antidepressivnoi effektivnosti. Dnevnik Psikhiatra. 2015;4:14-16. (In Russ.)
Tu KY, Wu MK, Chen YW, Lin PY, Wang HY, Wu CK, Tseng PT. Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA. Medicine (Baltimore). 2016;95(4):e2411. https://doi.org/10.1097/MD.0000000000002411
Cipriani A, Furukawa TA, Salanti G, Geddes J, Higgins J, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet. 2009;373(9665):746-758. https://doi.org/10.1016/s0140-6736(09)60046-5
Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-Salva M-A. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. International Clinical Psychopharmacology. 2013;28:12-19. https://doi.org/10.1097/YIC.0b013e328359768e
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;17(12):CD008851. https://doi.org/10.1002/14651858.CD008851.pub2
Demyttenaere K, Corruble E, Hale A, Quera-Salva M-A, Picarel-Blanchot F, Kasper S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectrums. 2013;18:163-170. https://doi.org/10.1017/S1092852913000060
Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888. https://doi.org/10.1136/bmj.g1888
Drobizhev MYu. Time for meta-analyses and efficacy of antidepressants in depression. Sotsial’naya i Klinicheskaya Psikhiatriya. 2017;4:81-88. (In Russ.)
Khoo AL, Zhou HJ, Teng M, Lin L, Soh YJL, Mok YM, Lim BP, Gwee KP, Network Meta-Analysis and Cost-Effectiveness Generation Antidepressants. CNS Drugs. 2015;29(8):695-712. https://doi.org/10.1007/s40263-015-0267-6
Frolova VI. Network meta-analysis of new generation antidepressants. Psychiatry and Psychopharmacotherapy (P.B. Gannushkin Journal). 2016;18(6):21-25. (In Russ.)
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Avedisova AS, Zakharova KV, Marachev MP. The results of observational studies JAZZ: remission, predictors of its formation and tolerability of Valdoxane (agomelatine) in patients with anxious depression within major depressive disorder. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2013;6:14-22. (In Russ.)
Volel BA. Safety and efficacy of agomelatine in the treatment of anxiety and depressive disorders in clinical practice (based on OCTAVA protocol). Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2015;17(2):9-14. (In Russ.)
Vorobyova OV. Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study «Resonance». Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;9:47-51. (In Russ.)
Ivanov SV. Val’doksan (agomelatin) pri terapii umerennyKh i tyazhelykh depRessii nepsikhOticheskogo urovNya v ambulatOrnoi i goSpital’noi praktike (rezul’taty Rossiiskogo mul’ti_tsentrovogo issledovaniya «KhRONOS»). Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2009;6:14-17. (In Russ.)
Medvedev VE. Treatment of mild and moderate Major Depressive Disorder with Valdoxane (agomelatine) in patients with cardiovascular disorders: results of the National Observational Multicenter Study PULSE. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2014;5:30-35. (In Russ.)
Medvedev VE, Retyunsky KY, Ovchinnikov AA, Baryl’nik YuB, Shmilovich AA, Antokhin EYu, Usov GM, Cheremin RA, Poletsky VM, Onegin AV, Kireeva IP, Frolova VI, Filippova NV, Antonova AA, Deeva MA, Onegina DA. The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study «EMOTSIA»). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(11):26-34. (In Russ.) https://doi.org/10.17116/jnevro201611611126-34
Tsygankov BD, Yaltonskaya AV, Filippskikh SV. Val’doksan (Agomelatin) v terapii tyazhelykh i umerennykh depressii nepsikhoticheskogo urovnya (rezul’taty observatsionnogo issledovaniya). Obozrenie Psikhiatrii i Meditsinskoi Psikhologii im. V.M. Bekhtereva. 2011;1:37-40. (In Russ.)
Yakhno NN, Voznesenskaya TG. Efficacy and tolerance of agomelatin (Valdoxan) in the treatment of mild and moderate depression in neurologic practice (the results of Russian multicenter research «CAMERTON»). Nevrologicheskii Zhurnal. 2012;1:43-49. (In Russ.)
Medvedev VE. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disorders: results of the National Multicenter Observational Study PULSE. Neuropsychiatric Disease and Treatment. 2017;13:1141-1151. https://doi.org/10.2147/ndt.s129793
Medvedev VE, Retyunskii KYu, Ovchinnikov AA, Baryl’nik YuB, Shmilovich AA, Antokhin EYu, Usov GM, Cheremin RA, Poletskii VM, Onegin AV, Kireeva IP, Frolova VI, Filippova NV, Antonova AA, Deeva MA, Onegina DA. Differences in Assessment of the Severity of Depression by Doctors and Patients during Combined Therapy with Agomelatine (the EMOTION multicenter trial). Neuroscience and Behavioral Physiology. 2018;48(3):367-376. https://doi.org/10.1007/s11055-018-0572-x
Medvedev VE. Valdoxane (agomelatine) in combined therapy of moderate and severe non-psychotic depressions. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(5-1):37-40. (In Russ.)
Medvedev VE. Dysphoric Depression Monotherapy with Valdoxan. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2016;18(1):20-23. (In Russ.)
Medvedev VE. Combined anti-depressive therapy with Valdoxan (agomelatin) and antipsychotics. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2012;2:20-23. (In Russ.)
Medvedev VE. Possibility of combined antidepressive therapy with melatonergic and tricyclic antidepressants. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2012;1:53-56. (In Russ.)
Medvedev VE. Treatment of non-psychotic depressions in the framework of involutional hysteria (experience of Valdoxan use). Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2011;4:14-18. (In Russ.)
Medvedev VE. Perspektivy ispol’zovaniya melatoninergicheskikh preparatov v terapii depressii u patsientov s serdechno-sosudistymi zabolevaniyami. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2010;3:19-23. (In Russ.)
Medvedev VE, Barsegyan TV. Assessment of the efficacy and tolerability of melatonergic antidepressant treatment in patients surgical correction of the appearance. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(11-2):3-9. (In Russ.) https://doi.org/10.17116/jnevro20141141123-9
Medvedev VE, Epifanov AV. Treatment of depression in general hospital patients with arterial hypertension. Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2012;5:14-18. (In Russ.)
Medvedev VE, Epifanov AV. Innovation method of depression treatment in patients with coronary artery disease. Obozrenie Psikhiatrii i Meditsinskoi Psikhologii im. V.M. Bekhtereva. 2010;3:31-36. (In Russ.)
Medvedev VE, Gushanskaya EV, Ter-Israelyan AU. Treatment of depression with symptoms of anhedonia: experience of agomelatine (Valdoxan). Psychiatry and Psichopharmacotherapy (P.B. Gannushkin Journal). 2014;3:45-49. (In Russ.)
Medvedev VE, Epifanov AV, Zverev KV. Preventive and cessation therapy of mental disorders in patients with the acute coronary syndrome. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(4):42-48. (In Russ.)
Medvedev VE, Ter-Israelyan AYu, Frolova VI, Korovyakova EA, Gushanskaya EV. Treatment of depression with cognitive impairment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova 2018;118(2):77-80. (In Russ.) https://doi.org/10.17116/jnevro20181182177-80
Medvedev VE, Frolova VI, Epifanov AV. New possibilities of pharmacotherapy in cardiovascular patients with mental disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(9):30-37. (In Russ.)
Chernova EV, Kozhechkina OV, Ter-Israelyan AYu, Medvedev VE. Agomelatine (valdoxan) in treatment of endogenous depression in day patient department. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(10):43-46. (In Russ.) https://doi.org/10.17116/jnevro201611610143-46
Medvedev VE. Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression. Neuroscience and Behavioral Physiology. 2013;7(43):878-882. https://doi.org/10.1007/s11055-013-9822-0
Medvedev VE, Chobanu IK, Frolova VI, Zuikova NL, Epifanov AV. Effektivnost’ psikhofarmakoterapii i psikhoterapii u patsientov s serdechno-sosudistymi zabolevaniyami. Russian Archives of Internal Medicine. 2013;5:61-66. (In Russ.) https://doi.org/10.20514/2226-6704-2013-0-5-61-66
Billioti de Gage S, Collin C, Le Tri T, Pariente A, Dray-Spira R, Zureik M. Hepatotoxicity of agomelatine and other antidepressants versus selective serotonin reuptake inhibitors. Paris: Programme of the 30th ECNP Congress; 2017.